System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Florian Clatot is an expert in Oncology at Centre Henri Becquerel (France). As of October 2026, ScienceLeadR ranks Florian Clatot in the top 1% of experts worldwide for Squamous Cell Carcinoma of Head and Neck, Breast Diseases and Breast Neoplasms. Florian Clatot has authored 192 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 12 of them ongoing. SLR score: 1,069 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Florian Clatot Centre Henri Becquerel France
1 069 ScienceLeadR Reputation 1069

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy - Biochemistry - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 192

Citations

Citations: 3 209 1st author: 18 Last author: 43 Unique author: 1

Main journals

Ann Oncol 29
J Clin Oncol 23
Cancer Res 13
Eur J Cancer 9
Oral Oncol 8

Best Journals

J Clin Oncol 19
Ann Oncol 16
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cerebrospinal fluid circulating tumor DNA profiling in central nervous system metastases from solid tumors: A prospective multicentre translational analysis of the BrainStorm (OncoDistinct-006) study.
PMID 42835688 — genes, dna fingerprinting, circulating tumor dna, neoplasms, central nervous system, neoplasm metastasis, nervous system, tissues, plasma		J Liq Biopsy20260
Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study).
PMID 42612404 — cells, cetuximab, carcinoma, squamous cell, drug therapy, squamous cell carcinoma of head and neck, therapeutics, chemotherapy		Oral Oncol20260
Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.
PMID 42580099 — breast neoplasms, neoplasms, drug therapy, chemotherapy, adjuvant, breast, anthracyclines, genes, brca1, chemotherapy		Eur J Cancer20260
Letter to Editor Following "Visualization of Scattered Tumor Regression Following Neoadjuvant Chemoimmunotherapy With a Novel Intraoperative PET/CT Scanner".
PMID 42538502 — neoplasms, positron emission tomography computed tomography		Head Neck20260
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.
PMID 42470471 — cetuximab, neoplasms, head and neck neoplasms, pharmacokinetics		Cancer Chemother Pharmacol20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 3 12
N/A 9
Phase 2 6
Phase 1/Phase 2 3

By status:

Recruiting 14
Completed 10
Active not recruiting 2
Unknown 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 28
Observational 2

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 1
multicentricup10 21

Main Topics

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 study to evaluate petosemtamab vs investigator s choice in previously treated metastatic recurrent head and neck cancer
2023-510322-32-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Active not recruiting2025
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first line treatment of head and neck cancer
2023-510323-30-00 — cells, safety, carcinoma, squamous cell, neoplasms, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carcinoma, head, neck		Phase 3Recruiting2025
Evaluation of a new radiotracker for predicting complete response after neoadjuvant chemotherapy in HER2 positive early breast cancer
2025-523286-23-00 — single-domain antibodies, breast neoplasms, polymerase chain reaction, neoplasms, drug therapy, positron emission tomography computed tomography, breast, chemotherapy		Phase 1/Phase 2Recruiting2026
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent Metastatic Head and Neck Cancer
2025-521917-24-00 — cells, carcinoma, squamous cell, neoplasms, fluorouracil, squamous cell carcinoma of head and neck, head and neck neoplasms, therapeutics, carboplatin, carcinoma, head, neck		Phase 3Not yet recruiting2026
Study of Taxane Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2023-510559-41-00 — cells, cetuximab, carcinoma, squamous cell, drug therapy, maintenance, squamous cell carcinoma of head and neck, chemotherapy, carcinoma, head, neck		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS